Fig 2: Functional analysis of MP-HJ-1b on HeLa cells.A Heatmap showing the differential expression of proteins related to ribosomes, mitochondria, and ATP with MP-HJ-1b and colchicine treatment. B Western blotting analysis of RPL35 (a ribosome protein) and MRPL28 (a mitoribosome protein). C Intracellular ATP measurement after 1 h of MP-HJ-1b and colchicine treatment. (t tests, *P < 0.05, **P < 0.01).

Fig 3: MP-HJ-1b and colchicine affect the ferroptosis pathway in HeLa cells.A Intracellular ROS measurement by flow cytometry after treatment with the two compounds. (Marker, BODIPYTM 581/591 C11). B MP-HJ-1b and colchicine increase Fe2+ concentrations in HeLa cells. (t tests, *P < 0.05). C MP-HJ-1b and colchicine increase the concentration of MDA in HeLa cells. (t tests, *P < 0.05). D MP-HJ-1b and colchicine decrease intracellular G-SH levels. (t tests, *P < 0.05). E Electron micrograph. (magnification, 30000×; red arrow, mitochondrion; red rectangle, nucleus). F Western blotting analysis for SLC7A11, GPX4, LC3A/B, RPL35, and MRPL28. Ferrostatin-1 (fer-1) is a ferroptosis inhibitor. G Schematic of the mechanism by which the two compounds promote ferroptosis.